search
gene editing
Trends
- 1Epigenetic editing banishes hepatitis B virus in study●'Epigenetic' editing banishes hepatitis B virus
Researchers report that epigenetic editing can silence hepatitis B virus, effectively banishing it rather than merely suppressing it. The approach targets the virus's gene activity without cutting DNA, offering a possible route toward a functional cure for a infection that affects hundreds of millions and is a leading cause of liver cancer. Readers are discussing the promise and hurdles before human use.
- 2Single CRISPR Treatment Halves Bad Cholesterol for a Year▼One CRISPR treatment cut “bad” cholesterol in half for a full year
A one-time CRISPR gene-editing treatment reportedly cut LDL, or "bad," cholesterol roughly in half, with effects lasting a full year. The finding suggests gene editing could one day offer a durable alternative to daily statins for people at risk of heart disease. Coverage is drawing attention to the potential of permanent, single-dose therapies for one of the world's leading causes of death, though longer and larger trials will be needed before wide use.
- 3Engineered mini CRISPR enzyme gets 60-fold power boost▼Engineered mini CRISPR enzyme gets a 60-fold power boost for gene editing
Researchers report engineering a compact CRISPR enzyme with a 60-fold increase in gene-editing power. The mini enzyme, if validated, could make gene therapies more efficient with smaller delivery vehicles, a key limitation in current CRISPR treatments. Coverage in the biology community highlights the size-and-strength tradeoff as a notable advance for therapeutic and research applications.
- 4Epigenetic Editing Edges Closer to Clinical Use▼Epigenetic Editing Steps Closer to the Clinic as Bioengineering Tools Mature
Reports say epigenetic editing — altering gene activity without changing DNA sequence — is moving closer to clinical application as the bioengineering tools behind it mature. Unlike CRISPR-style gene cutting, epigenetic approaches aim to switch genes on or off reversibly, and researchers see growing potential for treating disease with fewer permanent risks. The field is watching which tools and trials will translate first.
- 5What's The Latest On CRISPR Gene Editing Technology?▼What’s The Latest On CRISPR Gene Editing Technology?
Forbes is asking what the latest developments are in CRISPR gene editing technology. The field continues to move quickly, with gene-editing therapies and research advancing across medicine and biotechnology. Readers are following the topic as new treatments and regulatory decisions keep gene editing in the public eye.
- 6Anthropic claims Claude AI discovered new gene-editing enzyme▼Anthropic says Claude found a new gene-editing enzyme but science isn't confirmed
Anthropic says its Claude AI helped identify a previously unknown gene-editing enzyme, a claim that would be notable if verified. The company itself acknowledges the finding has not been independently confirmed or validated through peer review, so scientists are treating the announcement with caution until laboratory evidence backs it up.
- 7Gene editing seen as a tool against global food insecurity●The shining promise of gene editing technology in a food-insecure world
Commentary is highlighting gene editing technology as a promising answer to food insecurity worldwide. The piece argues that tools allowing precise changes to crops and livestock could help farmers produce more food under difficult conditions, including climate pressure and shrinking resources. It adds to an ongoing debate over how gene-edited foods should be regulated and accepted by the public.
- 8CRISPR-Edited Plants Need a Sustainable Innovation System▼CRISPR Beyond the Lab: Why Genome-Edited Plants Need a Sustainable Innovation System
Commentary argues that CRISPR genome-edited plants must move beyond laboratory success into a broader sustainable innovation system covering regulation, farming practice and commercialisation. The piece stresses that editing crops is only one step; lasting impact depends on infrastructure, policy and responsible deployment in agriculture.
- 9Study maps rational selection of adenine base editors for human genome editing●Rational selection of SpCas9 and variant-derived adenine base editors for human genome editing
A Nature publication describes a rational framework for choosing between SpCas9 and variant-derived adenine base editors when editing the human genome. The work aims to help researchers match editor choice to specific target sites and desired edits, improving precision in gene-editing applications. The paper is being circulated among readers following advances in CRISPR-based genome editing tools.